Genmab — Juni 2015
-
Medmindre Genmab har noget helt unikt egenudviklet
-
Jan har jo lovet os en præklinisk opdatering i år
-
Nyt Daratumumab "på Clinical Trials: https://clinicaltrials.gov/ct2/show/NCT02477891?term=daratumumab&rank=12&submit_fld_opt=
-
The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available for subjects with multiple myeloma who have received at least 3 prior lines of therapy
-
-
Aabo er satme genial
-
IV1989: Hvad er forskellen i på DARA /kontra REVLIMID, hvorfor tror vi at lægerne hellere vil bruge DARA kontra REVLIMID ? citat Peter Aabo: "Revlimid, et af de medikamenter der betragtes som en hjørnesten i dagens behandling af myelomatose, omsætter for mere end 5 mia. dollars årligt. Vi vurderer på den baggrund, at Daratumumab der ligeledes er godt på vej til at etablere sig som et basislægemiddel i behandlingen af myelo¬matose, bør kunne opnå et peaksale på min. 5 mia. dollars årligt i 2025
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind